← Back
Data updated: Mar 10, 2026
HUMANWELL
Oncology
HUMANWELL is a generic drug manufacturer focused on Oncology.
2024
Since
2
Drugs
-
Trials
108
Approved (2yr)
Key Drugs
No active drugs
Recent Activity
GABAPENTIN 2026-02-24
Labeling
GABAPENTIN 2026-02-18
Labeling
GABAPENTIN 2026-02-17
Labeling
GABAPENTIN 2026-02-17
Labeling
GABAPENTIN 2026-02-12
Labeling
TAPENTADOL HYDROCHLORIDE 2026-02-10
GABAPENTIN 2026-01-29
Labeling
GABAPENTIN 2026-01-29
Labeling
TAPENTADOL HYDROCHLORIDE 2026-01-27
TAPENTADOL HYDROCHLORIDE 2026-01-26
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Oncology 100%
0 drugs Phase 1: 2
Pipeline Strength Pro
Loading...
Active (0)
Discontinued (1)
Company Info
- First Approval
- 2024-02-26
- Latest
- 2026-01-27
- Applications
- 2